TY  - JOUR
AU  - Park, Su-Yeon
AU  - Pylaeva, Ekaterina
AU  - Bhuria, Vikas
AU  - Gambardella, Adriana Rosa
AU  - Schiavoni, Giovanna
AU  - Mougiakakos, Dimitrios
AU  - Kim, Sung-Hoon
AU  - Jablonska, Jadwiga
TI  - Harnessing myeloid cells in cancer.
JO  - Molecular cancer
VL  - 24
IS  - 1
SN  - 1476-4598
CY  - London
PB  - Biomed Central
M1  - DKFZ-2025-00493
SP  - 69
PY  - 2025
AB  - Cancer-associated myeloid cells due to their plasticity play dual roles in both promoting and inhibiting tumor progression. Myeloid cells with immunosuppressive properties play a critical role in anti-cancer immune regulation. Cells of different origin, such as tumor associated macrophages (TAMs), tumor associated neutrophils (TANs), myeloid derived suppressor cells (also called MDSCs) and eosinophils are often expanded in cancer patients and significantly influence their survival, but also the outcome of anti-cancer therapies. For this reason, the variety of preclinical and clinical studies to modulate the activity of these cells have been conducted, however without successful outcome to date. In this review, pro-tumor activity of myeloid cells, myeloid cell-specific therapeutic targets, in vivo studies on myeloid cell re-polarization and the impact of myeloid cells on immunotherapies/genetic engineering are addressed. This paper also summarizes ongoing clinical trials and the concept of chimeric antigen receptor macrophage (CAR-M) therapies, and suggests future research perspectives, offering new opportunities in the development of novel clinical treatment strategies.
KW  - Humans
KW  - Neoplasms: immunology
KW  - Neoplasms: therapy
KW  - Neoplasms: pathology
KW  - Animals
KW  - Myeloid Cells: immunology
KW  - Myeloid Cells: metabolism
KW  - Immunotherapy: methods
KW  - Tumor Microenvironment: immunology
KW  - Myeloid-Derived Suppressor Cells: immunology
KW  - Myeloid-Derived Suppressor Cells: metabolism
KW  - Eosinophils (Other)
KW  - Immunosuppression (Other)
KW  - Macrophages (Other)
KW  - Myeloid cells (Other)
KW  - Neutrophils (Other)
KW  - Therapeutic target (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40050933
DO  - DOI:10.1186/s12943-025-02249-2
UR  - https://inrepo02.dkfz.de/record/299549
ER  -